CombiGene are looking for broader opportunities

The EU decision to invest 3.36 MEUR in CombiGene’s development of gene therapy epilepsy treatment CG01 recently bore fruit as the company entered into an agreement with Spark Therapeutics for further development of the candidate. BioStock reached out to CEO Jan Nilsson for a comment as the company just received their last payment from the EU programme Horizon 2020. Strengthened by the large grant and triumphant deal, the company is looking to broaden its focus going forward.